SCHEMBL10169790

SCHEMBL10169790

CCOC(=O)C1(C)C(=O)c2sccc2[C@H]1c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 4/20 0.40
HTT P42858 2/20 0.40
KDM4E B2RXH2 3/20 0.37
CYP3A4 P08684 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.36
DHFR P00374 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ATM Q13315 1/20 0.34
OPRM1 P35372 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490408 0.83 HHAT (0.36) ALDH1A1HTTKDM4EMEN1KMT2A
SCHEMBL10169793 0.81 GAA (0.38) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL10169784 0.75 SMN1; SMN2 (0.43) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL490807 0.71 MEN1 (0.46) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL10169829 0.70 ALDH1A1 (0.37) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL17151297 0.65 MDM2 (0.44) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL15700868 0.65 MDM2 (0.44) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL15679212 0.65 MDM2 (0.44) GAASMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL13575457 0.64 BRD4 (0.39) GAASMN1; SMN2ALDH1A1KDM4ECYP3A4
SCHEMBL25061763 0.64 TSHR (0.44) GAASMN1; SMN2ALDH1A1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106046-B2 Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-31 US disclosed
US-8106046-B2 Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-31 US disclosed
US-20110105495-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed
US-20110105495-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105495-A1 CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF NFKB2, NFKB1, NFRKB GAA 4287/4885SMN1; SMN2 4710/4885ALDH1A1 2550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.